Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (13)

2022

  1. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

    Life science alliance, Vol. 5, Núm. 4

2020

  1. Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

    Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154

2018

  1. Executive summary of the consensus document on osteoporosis in HIV-infected individuals

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 312-314

2017

  1. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 3, pp. 844-849

2016

  1. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

    HIV Medicine, Vol. 17, Núm. 5, pp. 340-349

2015

  1. Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16

  2. Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47

  3. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

    HIV Medicine, Vol. 16, Núm. 6, pp. 370-374

2014

  1. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A clinical and molecular study

    PLoS ONE, Vol. 9, Núm. 2

  2. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  3. Peak bone mass in young HIV-infected patients compared with healthy controls

    Journal of Acquired Immune Deficiency Syndromes, Vol. 65, Núm. 2, pp. 207-212

  4. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

2013

  1. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: The RECOMB study

    HIV Medicine, Vol. 14, Núm. 6, pp. 327-336